JAHA:健康生活方式对预防药物使用者和非使用者的影响

2020-06-28 MedSci原创 MedSci原创

目前尚不清楚定期使用预防性药物的人是否与不使用药物的人一样从健康的生活方式中获益。本研究的目的旨在评估健康的生活方式是否与使用主要预防性药物包括阿司匹林、抗高血压药物和降脂药个体的死亡率相关。

目前尚不清楚定期使用预防性药物的人是否与不使用药物的人一样从健康的生活方式中获益。本研究的目的旨在评估健康的生活方式是否与使用主要预防性药物包括阿司匹林、抗高血压药物和降脂药个体的死亡率相关。

本研究纳入分析了来自2个不同临床研究的79043名女性和39544名男性,并根据体重指数、吸烟、体力活动、饮食和酒精摄入量定义了健康生活方式得分。最终共记录了35195次死亡事件,健康生活方式对降低死亡率的影响在预防性药物使用者和非使用者中无明显差异(P=0.54)。

研究结果显示,坚持健康的生活方式对预防药物的正常使用者和非使用者的降低死亡风险都有很大的益处。

原始出处:

Kai W et al.Healthy Lifestyle for Prevention of Premature Death Among Users and Nonusers of Common Preventive Medications: A Prospective Study in 2 US Cohorts.JAHA.2020 June.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660921, encodeId=6f681660921b8, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Fri Feb 05 20:52:30 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971590, encodeId=f5e019e1590b5, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Dec 21 12:52:30 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268281, encodeId=2242126828195, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jun 30 01:52:30 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371980, encodeId=4ce813e198041, content=<a href='/topic/show?id=ec702e877fb' target=_blank style='color:#2F92EE;'>#健康生活方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27877, encryptionId=ec702e877fb, topicName=健康生活方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jun 30 01:52:30 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660921, encodeId=6f681660921b8, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Fri Feb 05 20:52:30 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971590, encodeId=f5e019e1590b5, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Dec 21 12:52:30 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268281, encodeId=2242126828195, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jun 30 01:52:30 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371980, encodeId=4ce813e198041, content=<a href='/topic/show?id=ec702e877fb' target=_blank style='color:#2F92EE;'>#健康生活方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27877, encryptionId=ec702e877fb, topicName=健康生活方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jun 30 01:52:30 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660921, encodeId=6f681660921b8, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Fri Feb 05 20:52:30 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971590, encodeId=f5e019e1590b5, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Dec 21 12:52:30 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268281, encodeId=2242126828195, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jun 30 01:52:30 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371980, encodeId=4ce813e198041, content=<a href='/topic/show?id=ec702e877fb' target=_blank style='color:#2F92EE;'>#健康生活方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27877, encryptionId=ec702e877fb, topicName=健康生活方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jun 30 01:52:30 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-06-30 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660921, encodeId=6f681660921b8, content=<a href='/topic/show?id=a38b2e8752d' target=_blank style='color:#2F92EE;'>#健康生活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27875, encryptionId=a38b2e8752d, topicName=健康生活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48dd25178476, createdName=xiaoyang_ambs, createdTime=Fri Feb 05 20:52:30 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971590, encodeId=f5e019e1590b5, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Mon Dec 21 12:52:30 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268281, encodeId=2242126828195, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jun 30 01:52:30 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371980, encodeId=4ce813e198041, content=<a href='/topic/show?id=ec702e877fb' target=_blank style='color:#2F92EE;'>#健康生活方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27877, encryptionId=ec702e877fb, topicName=健康生活方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Jun 30 01:52:30 CST 2020, time=2020-06-30, status=1, ipAttribution=)]

相关资讯

JACC:经食道心超在结构性心脏病介入手术中的安全性研究

尽管经食道超声心动图(TEE)广泛应用于指导心脏结构性干预,但在这方面的安全性评估研究尚缺乏。本研究旨在评估心脏结构性干预中TEE操作后食管或胃损伤的发生率、并发症类型和相关因素。

JACC:左心耳封堵术和直接口服抗凝剂在高风险房颤患者中的比较研究

经皮左心耳闭合术(LAAC)在预防心房颤动(AF)相关卒中方面非劣于维生素K拮抗剂(VKAs)。然而,直接口服抗凝剂(DOACs)比VKAs具有更好的安全性,其对LAAC相关心血管和神经结局的影响尚不

JAHA:妊娠期高血压可明显增加未来心血管疾病风险

在评估妊娠合并妊娠高血压的妇女患心血管疾病风险的研究中发现了不一致的结论,本次荟萃分析旨在评估妊娠期高血压与孕妇心血管疾病风险的相关性。

JAHA:围产期妇女的体外生命支持临床研究

体外生命支持(ECLS)的使用已经扩大到包括围产期妇女等特殊人群。本系统回顾旨在量化文献报道的围产期妇女ECLS的病例数和适应证,以及报告与围产期ECLS相关的母婴并发症和结局。

JACC:心衰相关的临床研究发表率很低,应引起重视

临床试验结果报告不足会阻碍知识的传播,限制对治疗干预措施的理解,并可能最终伤害患者。本研究的目的旨在评估心力衰竭临床试验的发表率和预测因子,以及它们随时间的变化。

盘点:JACC六月第5期研究一览

1. 导管消融可明显降低患者房颤复发率